Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,623Revenue (TTM) $M15.0Net Margin (%)-838.3Altman Z-Score43.9
Enterprise Value $M3,271EPS (TTM) $-1.5Operating Margin %-879.1Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.8Pre-tax Margin (%)-838.3Higher ROA y-yY
Price/Book10.310-y EBITDA Growth Rate %--Quick Ratio13.4Cash flow > EarningsY
Price/Sales2415-y EBITDA Growth Rate %--Current Ratio13.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-27.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-31.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M86.8ROIC % (ttm)-474.2Gross Margin Increase y-yN

Gurus Latest Trades with NBIX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NBIXGeorge Soros 2016-09-30 Buy 0.02%$45.29 - $54.63
($49.8)
$ 41.71-16%New holding11,322
NBIXGeorge Soros 2016-06-30 Sold Out -0.01%$39.55 - $51.97
($45.94)
$ 41.71-9%Sold Out0
NBIXGeorge Soros 2016-03-31 Buy 0.01%$32.19 - $56.57
($40.01)
$ 41.714%New holding9,400
NBIXGeorge Soros 2013-09-30 Sold Out -0.03%$10.6 - $16.7
($13.79)
$ 41.71202%Sold Out0
NBIXGeorge Soros 2013-06-30 Buy 0.03%$10.9 - $13.57
($12.28)
$ 41.71240%New holding200,000
NBIXJoel Greenblatt 2012-12-31 Sold Out -0.13%$6.88 - $8.66
($7.6)
$ 41.71449%Sold Out0
NBIXJoel Greenblatt 2012-06-30 Add0.03%$6.31 - $8.06
($7.18)
$ 41.71481%Add 23.80%259,903
NBIXGeorge Soros 2012-06-30 Sold Out -0.02%$6.31 - $8.06
($7.18)
$ 41.71481%Sold Out0
NBIXJoel Greenblatt 2012-03-31 Buy 0.15%$7.33 - $9.79
($7.95)
$ 41.71425%New holding209,930
NBIXGeorge Soros 2012-03-31 Buy 0.02%$7.33 - $9.79
($7.95)
$ 41.71425%New holding150,000
NBIXGeorge Soros 2011-12-31 Sold Out -0.0018%$5.5 - $8.58
($6.76)
$ 41.71517%Sold Out0
NBIXGeorge Soros 2011-09-30 Reduce$5.59 - $8.44
($6.71)
$ 41.71522%Reduce -23.93%17,800
NBIXGeorge Soros 2011-06-30 Add$6.82 - $8.3
($7.54)
$ 41.71453%Add 90.24%23,400
NBIXGeorge Soros 2011-03-31 Add$6.47 - $7.84
($7.2)
$ 41.71479%Add 23.00%12,300
NBIXGeorge Soros 2010-12-31 Buy $5.99 - $8.53
($7.63)
$ 41.71447%New holding10,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NBIX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NBIX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
OBrien Christopher FlintChief Medical Officer 2016-11-15Sell25,000$52.84-21.06view
Lloyd-Smith MalcolmChief Regulatory Officer 2016-09-01Sell9,000$50-16.58view
OBrien Christopher FlintChief Medical Officer 2016-08-15Sell12,500$48.73-14.41view
Nevinny Corinne HDirector 2016-08-08Sell5,000$48.54-14.07view
Lloyd-Smith MalcolmChief Regulatory Officer 2016-05-31Sell9,000$50-16.58view
OBrien Christopher FlintChief Medical Officer 2016-05-31Sell12,500$50-16.58view
POPS RICHARD FDirector 2016-05-25Sell15,000$46.72-10.72view
OBrien Christopher FlintChief Medical Officer 2016-05-16Sell25,000$45-7.31view
Gano KyleChief Business Development Off 2016-04-11Sell41,770$44.02-5.25view
OBrien Christopher FlintChief Medical Officer 2016-04-06Sell25,000$45-7.31view

Quarterly/Annual Reports about NBIX:

News about NBIX:

Articles On GuruFocus.com
AbbVie: Encouraging Results From Elagolix Study Oct 20 2016 
Meridian Funds Comments on Neurocrine Biosciences Aug 31 2015 
Meridian Contrarian Fund Annual Report 2015 Aug 31 2015 
Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 

More From Other Websites
Neurocrine Biosciences to Present at the 2016 BMO Capital Markets Prescription for Success... Dec 07 2016
Hedge Funds Are Dumping CSRA Inc (CSRA) Dec 06 2016
Neurocrine Biosciences Announces INGREZZA™ (valbenazine) Long-Term Data to be Presented at the... Dec 05 2016
Uterine Fibroids Segment May Offer Opportunity for NBIX Dec 02 2016
ETFs with exposure to Neurocrine Biosciences, Inc. : December 2, 2016 Dec 02 2016
Neurocrine Biosciences Pursues Women’s Health Segment with Elagolix Dec 02 2016
NBIX Continues to Study Valbenazine for Tourette Syndrome Dec 02 2016
Why Valbenazine Studies Seem Promising Dec 01 2016
Should You Avoid Navient Corp (NAVI)? Dec 01 2016
Is Neurocrine Biosciences, Inc. (NBIX) a Good Stock to Buy? Dec 01 2016
Valbenazine May Become a Leading Therapy for Tardive Dyskinesia Dec 01 2016
Neurocrine Biosciences (Nasdaq: NBIX) to Ring The Nasdaq Stock Market Opening Bell Dec 01 2016
Why Neurocrine Biosciences May See Higher Losses in 2016 Dec 01 2016
Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : NBIX-US :... Dec 01 2016
Is Pool Corporation (POOL) A Good Stock To Buy? Nov 30 2016
Neurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA™ (valbenazine) New Drug... Nov 29 2016
Elagolix May Become a Strong Growth Driver for AbbVie Nov 29 2016
Coverage initiated on Neurocrine Biosci by Oppenheimer Nov 22 2016
Neurocrine Biosciences to Present at the 28th Annual Piper Jaffray Healthcare Conference Nov 21 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)